IL2RB and arthritic joint disease: DACLIZUMAB is a specific IL2 receptor-targeting drug, which is related to GZMB, IL2RB, and IL2RG, and research indicates its therapeutic potential in the experimental arthritis model induced by CIA (Brok et al., 2001).